Mechanism of bactericidal activity of microcin L in Escherichia coli and Salmonella enterica. 2011

Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
Laboratoire Littoral Environnement Sociétés, UMR 6250 CNRS-ULR, Université de La Rochelle, UFR Sciences, Bât. Marie Curie, Avenue Michel Crépeau, 17042 La Rochelle Cedex 01, France.

For the first time, the mechanism of action of microcin L (MccL) was investigated in live bacteria. MccL is a gene-encoded peptide produced by Escherichia coli LR05 that exhibits a strong antibacterial activity against related Enterobacteriaceae, including Salmonella enterica serovars Typhimurium and Enteritidis. We first subcloned the MccL genetic system to remove the sequences not involved in MccL production. We then optimized the MccL purification procedure to obtain large amounts of purified microcin to investigate its antimicrobial and membrane properties. We showed that MccL did not induce outer membrane permeabilization, which indicated that MccL did not use this way to kill the sensitive cell or to enter into it. Using a set of E. coli and Salmonella enterica mutants lacking iron-siderophore receptors, we demonstrated that the MccL uptake required the outer membrane receptor Cir. Moreover, the MccL bactericidal activity was shown to depend on the TonB protein that transduces the proton-motive force of the cytoplasmic membrane to transport iron-siderophore complexes across the outer membrane. Using carbonyl cyanide 3-chlorophenylhydrazone, which is known to fully dissipate the proton-motive force, we proved that the proton-motive force was required for the bactericidal activity of MccL on E. coli. In addition, we showed that a primary target of MccL could be the cytoplasmic membrane: a high level of MccL disrupted the inner membrane potential of E. coli cells. However, no permeabilization of the membrane was detected.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004751 Enteritis Inflammation of any segment of the SMALL INTESTINE. Enteritides
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001430 Bacteriocins Substances elaborated by specific strains of bacteria that are lethal against other strains of the same or related species. They are protein or lipopolysaccharide-protein complexes used in taxonomy studies of bacteria. Bacteriocin,Lantibiotic,Lantibiotics
D019779 Salmonella enterica A subgenus of Salmonella containing several medically important serotypes. The habitat for the majority of strains is warm-blooded animals.

Related Publications

Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
August 2001, Applied and environmental microbiology,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
December 2022, Microbiology spectrum,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
December 2004, American journal of veterinary research,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
March 1982, Antimicrobial agents and chemotherapy,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
July 2004, FEMS microbiology letters,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
July 2010, Gut microbes,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
January 2003, Letters in applied microbiology,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
August 1989, The Journal of clinical investigation,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
May 2004, Molecular microbiology,
Natacha Morin, and Isabelle Lanneluc, and Nathalie Connil, and Marie Cottenceau, and Anne Marie Pons, and Sophie Sablé
October 2000, Applied and environmental microbiology,
Copied contents to your clipboard!